Recombinant multi-species P27/KIP1/CDKN1B protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis

Genemedi produces recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine P27/KIP1/CDKN1B protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis.
This gene encodes a cyclin-dependent kinase inhibitor, which shares a limited similarity with CDK inhibitor CDKN1A/p21. The encoded protein binds to and prevents the activation of cyclin E-CDK2 or cyclin D-CDK4 complexes, and thus controls the cell cycle progression at G1. The degradation of this protein, which is triggered by its CDK dependent phosphorylation and subsequent ubiquitination by SCF complexes, is required for the cellular transition from quiescence to the proliferative state. Mutations in this gene are associated with multiple endocrine neoplasia type IV (MEN4). [provided by RefSeq, Apr 2014]
The Alternative Names of target: CDKN1B,CDKN4,Cdki1b,Cdkn1b,Cyclin-dependent kinase inhibitor 1B,Cyclin-dependent kinase inhibitor p27,KIP1,Kip1,MEN1B,MEN4,P27,P27KIP1,p27,p27Kip1

Target products collectionGo to P27/KIP1/CDKN1B products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No. Product Name Species Reactivity
GM-Tg-hg-T14006-Ag-1/ GM-Tg-hg-T14006-Ag-2 Human P27/KIP1/CDKN1B protein Human
GM-Tg-rg-T14006-Ag-1/ GM-Tg-rg-T14006-Ag-2 Rat P27/KIP1/CDKN1B protein Rat
GM-Tg-mg-T14006-Ag-1/ GM-Tg-mg-T14006-Ag-2 Mouse P27/KIP1/CDKN1B protein Mouse
GM-Tg-cynog-T14006-Ag-1/ GM-Tg-cynog-T14006-Ag-2 Cynomolgus/Rhesus macaque P27/KIP1/CDKN1B protein Cynomolgus/ Rhesus macaque
GM-Tg-felg-T14006-Ag-1/ GM-Tg-felg-T14006-Ag-2 Feline P27/KIP1/CDKN1B protein Feline
GM-Tg-cang-T14006-Ag-1/ GM-Tg-cang-T14006-Ag-2 Canine P27/KIP1/CDKN1B protein Canine
GM-Tg-bovg-T14006-Ag-1/ GM-Tg-bovg-T14006-Ag-2 Bovine P27/KIP1/CDKN1B protein Bovine
GM-Tg-equg-T14006-Ag-1/ GM-Tg-equg-T14006-Ag-2 Equine P27/KIP1/CDKN1B protein Equine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No. GM-Tg-hg-T14006-Ag-1/ GM-Tg-hg-T14006-Ag-2; GM-Tg-rg-T14006-Ag-1/ GM-Tg-rg-T14006-Ag-2;
GM-Tg-mg-T14006-Ag-1/ GM-Tg-mg-T14006-Ag-2; GM-Tg-cynog-T14006-Ag-1/ GM-Tg-cynog-T14006-Ag-2;
GM-Tg-felg-T14006-Ag-1/ GM-Tg-felg-T14006-Ag-2; GM-Tg-cang-T14006-Ag-1/ GM-Tg-cang-T14006-Ag-2;
GM-Tg-bovg-T14006-Ag-1/ GM-Tg-bovg-T14006-Ag-2; GM-Tg-equg-T14006-Ag-1/ GM-Tg-equg-T14006-Ag-2
Products Name P27/KIP1/CDKN1B protein
Species Human, Cynomolgus/ Rhesus macaque, rat, mouse, Feline, Canine, Bovine, Equine
Target Name P27/KIP1/CDKN1B
Protein Sub-location Introcelluar Protein
Isotypes Recombinant protein
Expression platform Mammalian cell
Bioactivity validation Affintiy&bioactivity validated by ELISA, cell culture validated.
Tag His
Products description Recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine P27/KIP1/CDKN1B protein was expressed in mammalian cell expression system and is expressed with 6 HIS tag at the C-terminus for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Purity Purity: ≥95% (SDS-PAGE)
Application In vitro study, in vivo study, benchmark, positive control for the diagnosis. Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference






    About Gmab

    GDU
    GDU

    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.